Literature DB >> 30159246

Pediatric melanoma and aggressive Spitz tumors: a retrospective diagnostic, exposure and outcome analysis.

Kelly M Bailey1,2, Alison B Durham3, Lili Zhao4, Doug Fullen5, James Geiger6, Carol Bradford7, Valerie Opipari1, Timothy Johnson3, Rajen Mody1.   

Abstract

BACKGROUND: The diagnosis and management of pediatric melanomas is challenging given the presence of both melanomas and histologically aggressive Spitz tumors of undetermined biological significance (S-UBS) in this age group. Study objectives were to examine: factors leading to diagnostic delays, therapy side effects and patient outcomes in these diagnostic groups.
METHODS: A retrospective case review was performed using The University of Michigan's pediatric oncology database over a 13-year timespan. Patients referred to our clinic for consideration of interferon therapy due to a diagnosis of a stage III melanoma or aggressive appearing S-UBS with significant lymph node involvement were included.
RESULTS: We found two major causes of diagnosis delay: patients with amelanotic lesions misdiagnosed as having a wart and cases reviewed by non-expert pathologists upfront. The side effects from interferon therapy requiring dose adjustments included neutropenia, thrombocytopenia and mood disturbances. There was wide variability in surveillance scan utilization, therefore leading to variability in patient radiation exposure. Unlike melanoma patients, none of the S-UBS patients experienced disease progression or death.
CONCLUSIONS: This study highlights the challenges with the initial clinical diagnosis and pathological sub-categorization of the pediatric S-UBS/melanoma spectrum of skin lesions and emphasizes the role of expert pathology review upfront. Further, education at the primary care level could improve accurate and timely diagnoses. Earlier diagnosis could spare patients from more extensive interventions, metastatic spread or adverse outcomes in this patient population. This study is limited due to its retrospective, single-institution perspective.

Entities:  

Keywords:  Melanoma; Spitz tumor; interferon

Year:  2018        PMID: 30159246      PMCID: PMC6087836          DOI: 10.21037/tp.2018.01.03

Source DB:  PubMed          Journal:  Transl Pediatr        ISSN: 2224-4336


  30 in total

1.  The feasibility of adjuvant interferon alpha-2b in children with high-risk melanoma.

Authors:  Fariba Navid; Wayne L Furman; Martin Fleming; Bhaskar N Rao; Sandra Kovach; Catherine A Billups; Alvida M Cain; Rex Amonette; Jesse J Jenkins; Alberto S Pappo
Journal:  Cancer       Date:  2005-02-15       Impact factor: 6.860

2.  Melanocytic tumors of uncertain malignant potential: results of a tutorial held at the XXIX Symposium of the International Society of Dermatopathology in Graz, October 2008.

Authors:  Lorenzo Cerroni; Raymond Barnhill; David Elder; Geoffrey Gottlieb; Peter Heenan; Heinz Kutzner; Philip E LeBoit; Martin Mihm; Juan Rosai; Helmut Kerl
Journal:  Am J Surg Pathol       Date:  2010-03       Impact factor: 6.394

Review 3.  Familial skin cancer syndromes: Increased melanoma risk.

Authors:  Katherine J Ransohoff; Prajakta D Jaju; Prajaka D Jaju; Jean Y Tang; Michele Carbone; Sancy Leachman; Kavita Y Sarin
Journal:  J Am Acad Dermatol       Date:  2016-03       Impact factor: 11.527

Review 4.  Management of melanomas in children and young adults.

Authors:  Michelle Neier; Alberto Pappo; Fariba Navid
Journal:  J Pediatr Hematol Oncol       Date:  2012-05       Impact factor: 1.289

5.  Pigmented epithelioid melanocytoma: favorable outcome after 5-year follow-up.

Authors:  Rajni V Mandal; Rajmohan Murali; Kurt F Lundquist; Bruce D Ragsdale; Peter Heenan; Stanley W McCarthy; Martin C Mihm; Richard A Scolyer; Artur Zembowicz
Journal:  Am J Surg Pathol       Date:  2009-12       Impact factor: 6.394

6.  Trends in pediatric melanoma mortality in the United States, 1968 through 2004.

Authors:  Kevan G Lewis
Journal:  Dermatol Surg       Date:  2007-12-17       Impact factor: 3.398

7.  The atypical Spitz tumor of uncertain biologic potential: a series of 67 patients from a single institution.

Authors:  Mathew W Ludgate; Douglas R Fullen; Julia Lee; Lori Lowe; Carol Bradford; James Geiger; Jennifer Schwartz; Timothy M Johnson
Journal:  Cancer       Date:  2009-02-01       Impact factor: 6.860

8.  Pigmented epithelioid melanocytoma: a low-grade melanocytic tumor with metastatic potential indistinguishable from animal-type melanoma and epithelioid blue nevus.

Authors:  Artur Zembowicz; J Aidan Carney; Martin C Mihm
Journal:  Am J Surg Pathol       Date:  2004-01       Impact factor: 6.394

9.  Adjuvant high-dose interferon for cutaneous melanoma is most beneficial for patients with early stage III disease.

Authors:  Daniel A Anaya; Yan Xing; Lei Feng; Xuelin Huang; Luis H Camacho; Merrick I Ross; Jeffrey E Gershenwald; Jeffrey E Lee; Paul F Mansfield; Janice N Cormier
Journal:  Cancer       Date:  2008-05-01       Impact factor: 6.860

Review 10.  Mechanism-driven biomarkers to guide immune checkpoint blockade in cancer therapy.

Authors:  Suzanne L Topalian; Janis M Taube; Robert A Anders; Drew M Pardoll
Journal:  Nat Rev Cancer       Date:  2016-04-15       Impact factor: 60.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.